From 25 to 27 March 2025, the GLIOMATCH consortium convened in Düsseldorf, Germany, for its third consortium meeting. The meeting was held in-person and hosted by the partner University of Düsseldorf (UDUS). Over 40 experts from across Europe gathered to assess progress of the past year and plan the next phase of the GLIOMATCH project.
Welcoming atmosphere and collaborative spirit
The three-day event kicked off with a welcome dinner, offering participants the chance to reconnect ahead of two intensive days of scientific exchange. The official meetings were held at the Haus der Universität in central Düsseldorf and covered a wide range of topics spanning clinical, technical, legal, and ethical dimensions of the project.
GLIOMATCH, a Horizon Europe project, aims to improve brain cancer treatment by harnessing immunotherapy and state-of-the-art technology, as described on our project page. One year after the project kick-off meeting in Leuven, Belgium, the team of experts met again to review progress, tackle challenges, and stay on track to reach its ambitious goals.
Haus der Universtität, Düsseldorf (meeting venue)
Clinical and ethical insights on Day 1
On Day 1, discussions on progress of the eight work packages kicked off. The first day was centred on the retrospective and prospective clinical trials (WP2 & WP5), including dedicated MRI and surgical working group sessions. Partners also explored the broader social and health-economic impacts of the project (WP6) and examined the ethical and legal roadmap for the GLIOMATCH clinical trials and data governance (WP1). A literature workshop rounded off the day before partners reconvened for a consortium dinner.
Snapshots from the meeting sessions and social activities
Progress review and planning on Day 2
Day 2 focused on the project’s technical and translational work, with in-depth sessions on mapping the tumour-host/immune micro-environment in glioblastoma (WP3/4). The consortium also reviewed ongoing developments around GLIOMATCH’s secure data platform and its data infrastructure, and outlined outreach and dissemination plans for 2025. A session dedicated to identifying and addressing inequalities in research (WP7) highlighted the project’s commitment to inclusive and responsible research practices. For more information on the GLIOMATCH work plan, visit our dedicated page.
Looking ahead
The meeting was a valuable opportunity for experts to discuss GLIOMATCH’s cross-disciplinary progress and to fine-tune the path forward in support of personalised immunotherapy for GBM and pHGG patients.
We extend our sincere thanks to the local hosts, Rüdiger Sorg and Angeliki Datsi (UDUS), for their warm hospitality and smooth organisation.
Organising team: Rüdiger Sorg (left) and Angeliki Datsi (right).
